{"id":"NCT02293902","sponsor":"Sanofi","briefTitle":"A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)","officialTitle":"A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2014-11-19","resultsPosted":"2018-01-30","lastUpdate":"2018-01-30"},"enrollment":243,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Sarilumab SAR153191 (REGN88)","otherNames":[]},{"type":"OTHER","name":"Placebo (for sarilumab)","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Folic acid","otherNames":[]}],"arms":[{"label":"Sarilumab 150 mg/150 mg","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg/200 mg","type":"EXPERIMENTAL"},{"label":"Placebo/Sarilumab 150 mg","type":"PLACEBO_COMPARATOR"},{"label":"Placebo/Sarilumab 200 mg","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\n-To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.\n\nSecondary Objective:\n\n-To assess the safety of sarilumab added to MTX in Japanese RA participants with an inadequate response to MTX.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":14.8,"sd":null},{"arm":"Sarilumab 150 mg","deltaMin":67.9,"sd":null},{"arm":"Sarilumab 200 mg","deltaMin":57.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":96,"countries":["Japan"]},"refs":{"pmids":["36305354","30894208"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":81},"commonTop":["Nasopharyngitis","Neutropenia","Stomatitis","Upper respiratory tract infection","Hepatic function abnormal"]}}